STOCK TITAN
  1. Home
  2. Sec-filings
  3. ROIV
  4. [Form 4] Roivant Sciences Ltd. Insider Trading Activity

[Form 4] Roivant Sciences Ltd. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Very Positive)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences Ltd. insider trading report: CEO and director Matthew Gline reported multiple transactions in Roivant common shares on 12/15/2025. He exercised stock options to buy 234,096 shares at $4.06 and a total of 3,636,563 shares at $12.68, then reported sales of 230,357, 566,116 and 943,527 shares at $21.68 per share. Additional share dispositions reflect “net settlement” of options to cover exercise prices. After these transactions, he reported beneficial ownership of 17,287,081 common shares held directly.

The filing notes that all options expiring in 2026 were exercised, eliminating that option position, and states that Gline has disgorged to Roivant the full amount of disgorgable profits from the sales as required by Section 16(b) of the Exchange Act.

Positive

  • None.

Negative

  • None.
Insider Gline Matthew
Role CEO
Sold 1,740,000 shs ($37.72M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 234,096 $0.00 --
Exercise Stock Option (Right to Buy) 1,363,711 $0.00 --
Exercise Stock Option (Right to Buy) 2,272,852 $0.00 --
Exercise Common Shares 234,096 $4.06 $950K
Sale Common Shares 230,357 $21.68 $4.99M
Other Common Shares 3,739 $21.68 $81K
Exercise Common Shares 1,363,711 $12.68 $17.29M
Sale Common Shares 566,116 $21.68 $12.27M
Other Common Shares 797,595 $21.68 $17.29M
Exercise Common Shares 2,272,852 $12.68 $28.82M
Sale Common Shares 943,527 $21.68 $20.46M
Other Common Shares 1,329,325 $21.68 $28.82M
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Shares — 17,521,177 shares (Direct)
Footnotes (1)
  1. All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934. Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options. Award of stock options to purchase Common Shares that is fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gline Matthew
(Last) (First) (Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY
(Street)
LONDON X0 SW1H 0DB
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO
3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 12/15/2025 M 234,096 A $4.06 17,521,177 D
Common Shares 12/15/2025 S 230,357 D $21.68(1) 17,290,820 D
Common Shares 12/15/2025 J 3,739(2) D $21.68(1) 17,287,081 D
Common Shares 12/15/2025 M 1,363,711 A $12.68 18,650,792 D
Common Shares 12/15/2025 S 566,116 D $21.68(1) 18,084,676 D
Common Shares 12/15/2025 J 797,595(2) D $21.68(1) 17,287,081 D
Common Shares 12/15/2025 M 2,272,852 A $12.68 19,559,933 D
Common Shares 12/15/2025 S 943,527 D $21.68(1) 18,616,406 D
Common Shares 12/15/2025 J 1,329,325(2) D $21.68(1) 17,287,081 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.06 12/15/2025 M 234,096 (3) 04/19/2026 Common Stock 234,096 $0 0 D
Stock Option (Right to Buy) $12.68 12/15/2025 M 1,363,711 (3) 03/31/2026 Common Stock 1,363,711 $0 0 D
Stock Option (Right to Buy) $12.68 12/15/2025 M 2,272,852 (3) 03/31/2026 Common Stock 2,272,852 $0 0 D
Explanation of Responses:
1. All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.
2. Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.
3. Award of stock options to purchase Common Shares that is fully vested.
By: /s/ Jo Chen, as Attorney-in-Fact for Matthew Gline 12/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR